High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer

PLoS One. 2015 Sep 16;10(9):e0138141. doi: 10.1371/journal.pone.0138141. eCollection 2015.

Abstract

Background: Cancer is caused by somatic DNA alterations such as gene point mutations, DNA copy number aberrations (CNA) and structural variants (SVs). Genome-wide analyses of SVs in large sample series with well-documented clinical information are still scarce. Consequently, the impact of SVs on carcinogenesis and patient outcome remains poorly understood. This study aimed to perform a systematic analysis of genes that are affected by CNA-associated chromosomal breaks in colorectal cancer (CRC) and to determine the clinical relevance of recurrent breakpoint genes.

Methods: Primary CRC samples of patients with metastatic disease from CAIRO and CAIRO2 clinical trials were previously characterized by array-comparative genomic hybridization. These data were now used to determine the prevalence of CNA-associated chromosomal breaks within genes across 352 CRC samples. In addition, mutation status of the commonly affected APC, TP53, KRAS, PIK3CA, FBXW7, SMAD4, BRAF and NRAS genes was determined for 204 CRC samples by targeted massive parallel sequencing. Clinical relevance was assessed upon stratification of patients based on gene mutations and gene breakpoints that were observed in >3% of CRC cases.

Results: In total, 748 genes were identified that were recurrently affected by chromosomal breaks (FDR <0.1). MACROD2 was affected in 41% of CRC samples and another 169 genes showed breakpoints in >3% of cases, indicating that prevalence of gene breakpoints is comparable to the prevalence of well-known gene point mutations. Patient stratification based on gene breakpoints and point mutations revealed one CRC subtype with very poor prognosis.

Conclusions: We conclude that CNA-associated chromosomal breaks within genes represent a highly prevalent and clinically relevant subset of SVs in CRC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Chromosome Breakage*
  • Clinical Trials, Phase III as Topic
  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / pathology
  • Genome-Wide Association Study*
  • Humans
  • Multicenter Studies as Topic
  • Mutation / genetics*
  • Prognosis
  • Randomized Controlled Trials as Topic

Substances

  • Biomarkers, Tumor

Associated data

  • GEO/GSE63216

Grants and funding

This study was financially supported by grants from the VUmc-Cancer Center Amsterdam (E. van den Broek) and the Dutch Cancer Society (KWF-2007-3832), and performed within the framework of the Center for Translational Molecular Medicine, DeCoDe project (grant 03O-101) and the Dutch Colorectal Cancer Group (DCCG). These funders had no role in study design, data collection, data analysis, decision to publish, or preparation of the manuscript.